Patents Assigned to Beth Israel Deaconess Medical Center, Inc.
  • Publication number: 20180177976
    Abstract: Apparatus and methods for producing narrow-band radiation in the green region of the visible spectrum are described. The narrow-band radiation may be used to aid subjects experiencing photophobia. In some cases, subjects may experience a reduction in pain (e.g., migraine photophobia) when using the narrow-band radiation.
    Type: Application
    Filed: June 17, 2016
    Publication date: June 28, 2018
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 10006089
    Abstract: Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mcl1 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mcl1. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: June 26, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Wenyi Wei
  • Patent number: 10000483
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 19, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nathanael Gray, Steven Balk, Qingsong Liu, Sen Chen
  • Patent number: 9995756
    Abstract: Described herein are, inter alia, methods for diagnosing and treating arrhythmogenic cardiomyopathy (ACM) by detecting cardiac intercalated disk proteins, e.g., desmosomal proteins, mechanical and gap junction proteins, in buccal cells. Exemplary desmosomal and gap junction proteins that can be evaluated in the methods described herein include plakoglobin, plakophilin 1, desmoplakin, and Cx43. The methods can also include selecting and/or administering a treatment for ACM to the subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 12, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey E. Saffitz, Angeliki Asimaki
  • Patent number: 9987302
    Abstract: The present invention relates to methods and compositions of treating patients suffering from, or at risk for, DNA damage and to increase life span, i.e., prevent or slow the aging process in all species. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: June 5, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Leo E. Otterbein
  • Patent number: 9987356
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: June 5, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Patent number: 9974788
    Abstract: The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: May 22, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Saumya Das, Alan C. Rigby
  • Patent number: 9974463
    Abstract: A device for determining muscle condition of a region of tissue. The device comprises an electrical impedance myography (EIM) portable probe bearing an electrode array. The electrode array comprises excitation electrodes used to apply multi-frequency electrical signals to the region of tissue and pickup electrodes that are used to collect electrical signals resulting from the application of the multi-frequency electrical signals to the region of tissue. To improve accuracy and reproducibility of EIM measurements, the electrode array is reconfigurable to select different subsets of excitation and pickup electrodes so that the electrodes are oriented differently with respect to muscle fibers. Additional devices may be associated with the EIM probe to measure such parameters as temperature, moisture content of the region, quality of contact of electrodes of the electrode array with a surface of the region and pressure with which the EEM probe is applied to the region.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: May 22, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Massachusetts Institute of Technology
    Inventors: Seward B. Rutkove, Joel L. Dawson
  • Patent number: 9964621
    Abstract: A method and apparatus for reducing scan time, eddy currents and image factors in dynamic magnetic resonance (MR) imaging associated with at least a portion a k-space. The method includes scanning at least a portion of the k-space with an Echo-Planar Imaging (EPI) pulse sequence technique, acquiring a randomly under-sampled k-space; and reconstructing the under-sampled k-space utilizing a constrained reconstruction technique. A dynamic image is constructed of the at least a portion of the k-space based on EPI and the randomly undersampled k-space techniques to each segment of the EPI pulse sequence technique.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: May 8, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Tamer Basha, Reza Nezafat
  • Publication number: 20180105540
    Abstract: The present invention includes 4-(hydroxymethyl)phenylboronic esters, which react with hydrogen peroxide to form 4-hydroxybenzyl alcohol, which is an anti-inflammatory and/or anti-oxidant compound, as well as microparticles and compositions thereof. In certain embodiments, the compositions of the invention may be used to treat or prevent oxidative stress and/or inflammation, including ischemic disease.
    Type: Application
    Filed: May 1, 2017
    Publication date: April 19, 2018
    Applicants: Beth Israel Deaconess Medical Center, Inc., Chonbuk National University Industrial Cooperation Foundation
    Inventors: Peter M. Kang, Dongwon Lee, Seunggyu Park, Dahee Jeong
  • Patent number: 9932370
    Abstract: The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 3, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Joseph Patrick Nkolola
  • Patent number: 9931313
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: April 3, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Patent number: 9932392
    Abstract: The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 3, 2018
    Assignees: CSL BEHRING AG, BETH ISRAEL DEACONESS MEDICAL CENTER INC
    Inventors: Ciaran Kelly, Xinhua Chen, Sylvia Miescher, Martin Spycher, Sandra Wymann, Adrian Zuercher
  • Patent number: 9925211
    Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 27, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: S. Ananth Karumanchi
  • Patent number: 9925261
    Abstract: Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 27, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Sharon Maynard, Vikas P. Sukhatme
  • Patent number: 9907848
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: March 6, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark A. Exley, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk
  • Publication number: 20180037614
    Abstract: Ultrasensitive and quantitative assays for detecting toxins of Clostridium difficile, which may involve digital ELISA, are provided. Also provided herein are differential detection assays that allow for distinguishing toxin B of highly virulent Clostridium difficile strains from toxin B of less virulent strains.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 8, 2018
    Applicants: Quanterix Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nira Pollock, Ciaran Kelly, David C. Duffy, Linan Song, Mingwei Zhao
  • Patent number: 9849300
    Abstract: Method and devices are provided for treating subjects with Transcranial Magnetic Stimulation (TMS). According to some approaches, the methods and devices are configured for the treatment of ongoing seizures. Other approaches relate to the use of TMS as an antiepileptogenic or for use in determining preferential placement of intracranial probes.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: December 26, 2017
    Assignees: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alvaro Pascual-Leone, Alexander Rotenberg, Iain Glass, Frances E. Jensen
  • Patent number: 9844564
    Abstract: The present invention includes a vanillyl alcohol-containing copolyoxalate copolymer (PVAX). The present invention also includes a PVAX microparticle comprising PVAX. In one aspect, the compositions of the invention can be used as a drug delivery system, an antioxidant or anti-inflammatory composition, a composition for preventing or treating ischemic disease, a composition for inhibiting the side effects of anticancer drugs, a contrast agent, and/or a composition for diagnosing ischemic disease.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: December 19, 2017
    Assignees: Industrial Cooperation Foundation Chonbuk University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dong Won Lee, Dong Hyun Hong, Peter M. Kang
  • Patent number: 9835705
    Abstract: A magnetic resonance imaging (MRI) system and methods are provided for producing images of a subject. In some aspects, a method includes identifying a point in the cardiac cycle, performing an inversion recovery (IR) pulse at a selected time point from the pre-determined point, and sampling a k-space segment at an inversion time from the IR pulse that is substantially coincident with the pre-determined point. The method also includes repeating the IR pulse and k-space sampling for multiple inversion times, and multiple segments of k-space, in an interleaved manner, to generate datasets having T1-weighted contrasts determined by their respective inversion times. The method further includes reconstructing three-dimensional (3D) spatially-aligned images using the datasets, and generating a T1 recovery map by combining the 3D images. In some aspects, a prospective/retrospective scheme may be used to obtain data fully sampled in the center of k-space and randomly undersampled in the outer regions.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 5, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Sebastian Weingartner, Mehmet Akcakaya, Reza Nezafat